The TNFRI promoter −1135C allele was significantly increased in the PTLD group compared with the transplant control group (71% vs 57%, P=0.03; Figure 1B;, Table 1) and also when compared with the healthy control group (71% vs 53%, P=0.002; Table 1). Here, TNFRSF1A is linked to post-transplant lymphoproliferative disease.